64 results
DEF 14C
SCNX
Scienture Holdings, Inc.
28 Aug 24
Information statement
4:05pm
of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from current … . Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial
PRE 14C
SCNX
Scienture Holdings, Inc.
15 Aug 24
Preliminary information
9:57pm
before being implemented. FDA regulations also require investigation and correction of any deviations from current GMPs and impose reporting … population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part
8-K
EX-10.2
SCNX
Scienture Holdings, Inc.
31 Jul 24
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
5:25pm
(the “SEC”); (ii) communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any
8-K
EX-10.3
SCNX
Scienture Holdings, Inc.
31 Jul 24
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
5:25pm
) communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including
8-K
EX-2.1
SCNX
Scienture Holdings, Inc.
31 Jul 24
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
5:25pm
or conducting a reasonably comprehensive investigation, consistent with such individual’s title or responsibilities, concerning the existence … , audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental
8-K
EX-10.2
ngp7wq0pg7v4
6 Mar 24
TRxADE Health, Inc. Announces Special Cash Dividend
8:30am
8-K
EX-10.1
eyl min4drqmq
6 Mar 24
TRxADE Health, Inc. Announces Special Cash Dividend
8:30am
8-K
EX-2.1
a967wnx62a9qb3e49
16 Feb 24
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-3.1
g8rg woibp7
11 Oct 23
Unregistered Sales of Equity Securities
4:05pm
425
EX-2.1
39a y0id67e000
14 Jul 23
Business combination disclosure
5:08pm
8-K
EX-2.1
t9e1w7lhct
14 Jul 23
TRxADE HEALTH, Inc. Amends Definitive Merger
5:07pm
425
EX-2.1
9cn vwkqen0dzrdeb2gb
30 Jun 23
Business combination disclosure
9:25am
8-K
EX-2.1
dmaze1npi39db0kog
30 Jun 23
Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger
9:25am
424B3
0go l33czlmnyk5o93ud
8 Dec 22
Prospectus supplement
5:05pm